Navigation Links
Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Date:4/25/2008

- 85% of patients achieve undetectable HCV RNA levels following 4 weeks of

treatment with R7128 1500mg BID with Pegasys(R) plus Copegus(R) - - Safety and tolerability comparable to placebo administered with Pegasys

plus Copegus -

- EASL presentation available on Pharmasset website - - Conference call scheduled for Friday, April 25, 2008 at 1:00 PM ET (US)

and 7:00 PM CEST (Milan) -

PRINCETON, N.J. and MILAN, Italy, April 25 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces the results of a 4-week Phase 1 clinical trial evaluating two oral dose levels of R7128 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in 50 treatment-naive patients chronically infected with hepatitis C virus (HCV) genotype 1. R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of HCV that is being developed through Pharmasset's collaboration with Roche. The results of this study were presented today at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) being held from April 23-27, 2008 in Milan, Italy.

In this study, R7128 demonstrated potent short-term antiviral activity and was generally safe and well tolerated. Eighty-five percent (85%) of patients receiving R7128 1500mg twice-daily (BID) with Pegasys plus Copegus for 4 weeks achieved undetectable HCV RNA levels with safety and tolerability comparable to placebo with Pegasys plus Copegus.

Dr. John McHutchison, professor of medicine at Duke University Medical Center and a clinical investigator for this study, stated, "R7128, in combination with Pegasys plus Copegus, has demonstrated Rapid Virologic Response (RVR)
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
2. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
3. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
6. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
7. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
8. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
9. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
10. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
11. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud Analytics, ... analytics technology, announces it is working with Intel ... for the new Lockheed Martin Healthcare Technology Alliance. ... health information technology providers, medical technology companies and ... and innovation to improve care in rapidly evolving ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Institute (C-Path), and TransCelerate BioPharma, Inc. are pleased to announce that data standards ... been published for use on the CDISC website . These three Therapeutic ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water needed, the refreshing ... as a simple way to get the natural ingredients that may help with ...
(Date:7/30/2015)... ... July 30, 2015 , ... Google recently announced that it will be disclosing ... discussed in a June 8, 2015 article published by Nasdaq , the powerful ... caused by its computer-driven cars, which such industry players as Tesla CEO Elon Musk ...
(Date:7/30/2015)... CA (PRWEB) , ... July ... ... recently released a video, “Beachside Nursing Center,” to announce its position as ... five-star ratings. Beachside's administrator and staff members support the CMS rating system, ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zejax is a New Way ... Training Capability , World renown body weight trainer, Paul Ziachik, announces today ... dramatically increases a person’s training capability. , The American College of Sports Medicine ...
Breaking Medicine News(10 mins):Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Beachside Nursing Center Releases New Video 2Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2
... , CHICAGO, Nov. 24 The holiday season can be ... But for many people, especially those recovering from an eating ... failures and anxiety about an uncertain future. Family gatherings with ... be challenging and sometimes awkward. , "In my ...
... , , FLINT, Mich., Nov. 24 ... insurance plans designed specifically for individuals 18 to 64 ... coverage directly. , The new HealthPlus Signature ... agents and brokers throughout the HealthPlus service area. More information, ...
... ... but research will be presented at the upcoming 2009 Advances in Inflammatory Bowel Diseases, ... that may identify a causative mutation for Crohn’s disease. , ... New York, NY (Vocus) November 24, 2009 ...
... , PITTSBURGH, Nov. 24 While the ... this time of the year can be difficult for those ... every day is difficult for children and families. The holiday ... , The Highmark Caring Place, A Center for Grieving Children, ...
... Ala., Nov. 24 HealthSouth Corporation (NYSE: HLS ) ... Lynch 2009 Credit Conference in New York on Dec. 2-3, 2009. ... be speaking on Thursday, Dec. 3, 2009, at 3:40 p.m. ET. ... http://investor.healthsouth.com by clicking on an available link. , ...
... rates didn,t differ greatly between high- and low-volume centers, ... Do hospitals that conduct the most angioplasties necessarily produce ... research had suggested that "practice makes perfect" when it ... over 30,000 patients finds low- and high-volume hospitals performing ...
Cached Medicine News:Health News:When Holiday Meals Aren't a Gift 2Health News:When Holiday Meals Aren't a Gift 3Health News:HealthPlus Offers New Insurance Plans for Consumers Seeking Health Coverage on Their Own 2Health News:HealthPlus Offers New Insurance Plans for Consumers Seeking Health Coverage on Their Own 3Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 3Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 4Health News:Highmark Caring Place Resources Help Children and Families Who Are Grieving During the Holidays 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 3
Extended angled sharp electrode - 1/box....
... 200, the state of the art in ... Zeiss optics with,the wide range of ICS ... as well as with an unusual scope ... stability and unique ergonomically designed. And Axiovert ...
... the way it implements the confocal principle, ... system is unmatched. It allows multi fluorescence ... and efficiency. Unprecedented flexibility for individual applications. ... guarantee fast and efficient structural and functional ...
... are the hallmark of these stereozoom fluorescent ... The top (incident) circular 9W fluorescent ring ... remaining cool to the touch. Binocular and ... to 44x zoom magnification or high-power 20x ...
Medicine Products: